A Real-world Study of Imraldi® Use

CompletedOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

June 30, 2019

Primary Completion Date

November 30, 2021

Study Completion Date

November 30, 2021

Conditions
Arthritis, Rheumatoid (RA)Axial Spondyloarthritis (axSpA)Arthritis, Psoriatic (PsA)Crohn's Disease (CD)Colitis, Ulcerative (UC)
Interventions
DRUG

Adalimumab

Administered as specified in the treatment arm

Trial Locations (54)

Unknown

Research Site, Bruges

Research Site, Brussels

Research Site, Genk

Research Site, Ghent

Research Site, Herentals

Research Site, Kortrijk

Research Site, Liège

Research Site, Sijsele

Research Site, Turnhout

Research Site, Berlin

Research Site, Bruchhausen-Vilsen

Research Site, Burghausen

Research Site, Dresden

Research Site, Elmshorn

Research Site, Erfurt

Research Site, Halle

Research Site, Hamburg

Research Site, Hamm

Research Site, Heidelberg

Research Site, Magdeburg

Research Site, Munich

Research Site, München

Research Site, Münster

Research Site, Oldenburg

Research Site, Ratingen

Research Site, Dublin

Research Site, Ancona

Research Site, Bari

Research Site, Florence

Research Site, Foggia

Research Site, Milan

Research Site, Modena

Research Site, Pavia

Research Site, San Giovanni Rotondo

Research Site, Siena

Research Site, Varese

Research Site, Almería

Research Site, Badajoz

Research Site, Donostia / San Sebastian

Research Site, Granada

Research Site, Mérida

Research Site, Sant Joan Despí

Research Site, Seville

Research Site, Terrassa

Research Site, Valladolid

Research Site, Ashford

Research Site, Bath

Research Site, Belfast

Research Site, Cambridge

Research Site, Kettering

Research Site, Luton

Research Site, Norwich

Research Site, Nottingham

Research Site, Sussex

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY